Gelomics: Revolutionizing Drug Development with AI-Powered Human Tissue Engineering

Christoph Meinert, Co-Founder & CEO of Gelomics, is transforming pharmaceutical research through the development of AI-powered human tissue cultures that replicate the complexity of real human organs, eliminating the need for traditional animal testing. His Brisbane-based biotech is providing a scalable and ethical alternative in an industry where over 90% of drugs fail despite $200 billion spent annually on development. By creating human microtissues that more accurately predict drug effectiveness, Gelomics is pioneering faster, safer, and more ethical drug development while attracting major pharmaceutical partnerships. Learn how this innovative platform is revolutionizing pharmaceutical research while setting new standards for ethical drug testing.